Drug Profile
Nanrilkefusp Alfa - SOTIO
Alternative Names: CYP 0150; CYP 0150 (RLI); IL-15-IL-15 receptor α fusion protein; Interleukin-15-interleukin-15 receptor alpha fusion protein; RLI; RLI 15; SO-C101; SOT-101; Super IL-15 cytokineLatest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Cytune Pharma
- Developer SOTIO
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-15 receptor agonists; Interleukin-2 receptor agonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- No development reported Malignant melanoma
Most Recent Events
- 13 Oct 2023 SOTIO Biotech and Merck Sharp & Dohme terminate a phase II trial for non-small cell lung cancer, colorectal cancer, cutaneous squamous cell carcinoma, hepatocellular carcinoma, castration-resistant prostate cancer, ovarian cancer (Combination therapy, Late-stage disease, Refractory metastatic disease) in Spain (SC) due to insufficient efficacy (NCT05256381)
- 13 Oct 2023 SOTIO Biotech terminates a phase II trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Belgium (SC) due to insufficient efficacy (NCT05619172)
- 24 Jan 2023 Phase-II clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Belgium (SC) as of January 2023 (EudraCT2022-001527-32)